Mc Guire Investment Group, LLC Editas Medicine, Inc. Transaction History

Mc Guire Investment Group, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$7.03 - $11.53 $13,715 - $22,495	-1,951 Reduced 11.67%	14,760 $107,000
Q4 2022 Jan 10, 2023	SELL	$8.32 - $13.21 $14,152 - $22,470	-1,701 Reduced 9.24%	16,711 $0
Q3 2022 Oct 13, 2022	SELL	$12.16 - $19.42 $13,935 - $22,255	-1,146 Reduced 5.86%	18,412 $225,000
Q2 2022 Jul 15, 2022	BUY	$9.99 - $21.35 $8,091 - $17,293	810 Added 4.32%	19,558 $231,000
Q1 2022 Apr 14, 2022	BUY	$14.08 - $27.63 $13,446 - $26,386	955 Added 5.37%	18,748 $357,000
Q4 2021 Jan 13, 2022	SELL	$26.55 - $40.57 $240,489 - $367,483	-9,058 Reduced 33.73%	17,793 $472,000
Q3 2021 Oct 19, 2021	SELL	$39.27 - $72.94 $24,543 - $45,587	-625 Reduced 2.27%	26,851 $1.1 Million
Q2 2021 Jul 16, 2021	SELL	$31.29 - $56.64 $23,842 - $43,159	-762 Reduced 2.7%	27,476 $1.56 Million
Q1 2021 Apr 20, 2021	BUY	$39.71 - $90.58 $669,034 - $1.53 Million	16,848 Added 147.92%	28,238 $1.19 Million
Q4 2020 Jan 13, 2021	BUY	$27.07 - $84.35 $23,063 - $71,866	852 Added 8.09%	11,390 $799,000
Q3 2020 Oct 19, 2020	SELL	$28.06 - $37.16 $3,731 - $4,942	-133 Reduced 1.25%	10,538 $296,000
Q2 2020 Jul 14, 2020	BUY	$18.5 - $34.34 $197,413 - $366,442	10,671 New	10,671 $316,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Mc Guire Investment Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Mc Guire Investment Group, LLC with notifications on news.